Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study.

Drakopoulos P, van de Vijver A, Parra J, Anckaert E, Schiettecatte J, Blockeel C, Hund M, Verhagen-Kamerbeek WDJ, He Y, Tournaye H, Polyzos NP

Frontiers in endocrinology26 Feb 2019Cited by 4 (Europe PMC)

PMID30863367PMCIDPMC6399150DOI10.3389/fendo.2019.00115PepBankPUB-30863367

Download PDF PubMedAsk about this study

Jump to 4 results

Summary

Research Question: What is the effect of gonadotropin-releasing hormone (GnRH)-agonist treatment on serum anti-Müllerian hormone (AMH)? Design: This prospective cohort study conducted in a tertiary university hospital comprised patients (n = 52) who self-administered daily triptorelin (0.1 mg/0.1 mL) subcutaneously for 14 days from menstrual cycle day 21 ± 3, between July 2015 and March 2016. Enrolled women were 18-43 years old, considered normal ovarian responders, with a planned GnRH agonist controlled ovarian stimulation protocol. The primary endpoint was to evaluate the effect of GnRH agonist on serum AMH levels after 7 and 14 days of treatment. Results: Under GnRH agonist treatment, serum AMH was significantly decreased vs. baseline on day 7 (mean change from baseline: -0.265 ng/mL; 95% confidence interval [CI], -0.395 to -0.135 ng/mL; p < 0.001). On day 14, serum AMH was significantly increased (mean change from baseline: 0.289 ng/mL; 95% CI, 0.140-0.439 ng/mL; p < 0.001). Although the median change in AMH from baseline was only -14.9% on day 7 and +17.4% on day 14, from day 7 to 14 AMH significantly increased by 0.55 ng/mL (43.8%; p < 0.001), which is of paramount clinical importance. A linear, mixed-effect model demonstrated that GnRH agonist treatment for 7 and 14 days had a highly significant effect on serum AMH concentration after adjustment for confounding factors (age, body mass index, baseline antral follicle count, and visit). AMH assay precision was excellent (four aliquots/sample); coefficient of variation was 1.2-1.4%. Conclusions: GnRH agonist treatment had a clinically significant effect on serum AMH, dependent on treatment duration. The clear V-shaped response of AMH level to daily GnRH agonist treatment has important clinical implications for assessing ovarian reserve and predicting ovarian response, thus AMH measurements under GnRH agonist downregulation should be interpreted with great caution.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In normal ovarian responders, triptorelin treatment was linked to a serum AMH decrease of 0.265 ng/mL at day 7 versus baseline.
In plain wordsIn normal ovarian responders, triptorelin was linked to lower serum AMH at day 7 compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseAMH change at day 7
Study
n = 52
Comparator
Baseline
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
AMH mean change
−0.265 ng/mL
day 7 versus baseline
AMH median change from baseline
−14.9%
day 7 versus baseline
Source sentences
Summary
Under GnRH agonist treatment, serum AMH was significantly decreased vs. baseline on day 7 (mean change from baseline: -0.265 ng/mL; 95% confidence interval [CI], -0.395 to -0.135 ng/mL; p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Although the median change in AMH from baseline was only -14.9% on day 7 and +17.4% on day 14, from day 7 to 14 AMH significantly increased by 0.55 ng/mL (43.8%; p < 0.001), which is of paramount clinical importance.
Summary · context
This prospective cohort study conducted in a tertiary university hospital comprised patients (n = 52) who self-administered daily triptorelin (0.1 mg/0.1 mL) subcutaneously for 14 days from menstrual cycle day 21 ± 3, between July 2015 and March 2016.
Summary · context
Enrolled women were 18-43 years old, considered normal ovarian responders, with a planned GnRH agonist controlled ovarian stimulation protocol.
Show in the study text Report a problemFND-3086336701
02HumanObservational studyEfficacy outcome
In normal ovarian responders, triptorelin treatment was linked to a serum AMH increase of 0.289 ng/mL at day 14 versus baseline.
In plain wordsIn normal ovarian responders, triptorelin was linked to higher serum AMH at day 14 compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAMH change at day 14
Study
n = 52
Comparator
Baseline
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
AMH mean change
0.289 ng/mL
day 14 versus baseline
AMH median change from baseline
17.4%
day 14 versus baseline
Source sentences
Summary
On day 14, serum AMH was significantly increased (mean change from baseline: 0.289 ng/mL; 95% CI, 0.140-0.439 ng/mL; p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Although the median change in AMH from baseline was only -14.9% on day 7 and +17.4% on day 14, from day 7 to 14 AMH significantly increased by 0.55 ng/mL (43.8%; p < 0.001), which is of paramount clinical importance.
Summary · context
This prospective cohort study conducted in a tertiary university hospital comprised patients (n = 52) who self-administered daily triptorelin (0.1 mg/0.1 mL) subcutaneously for 14 days from menstrual cycle day 21 ± 3, between July 2015 and March 2016.
Summary · context
Enrolled women were 18-43 years old, considered normal ovarian responders, with a planned GnRH agonist controlled ovarian stimulation protocol.
Show in the study text Report a problemFND-3086336702
03HumanObservational studyEfficacy outcome
In normal ovarian responders receiving triptorelin, serum AMH increased by 0.55 ng/mL from day 7 to day 14.
In plain wordsIn normal ovarian responders receiving triptorelin, serum AMH increased from day 7 to day 14.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAMH change from day 7 to day 14
Study
n = 52
Comparator
Day 7
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
AMH change
0.55 ng/mL
day 7 to day 14
AMH relative increase
43.8%
day 7 to day 14
Source sentences
Summary
Although the median change in AMH from baseline was only -14.9% on day 7 and +17.4% on day 14, from day 7 to 14 AMH significantly increased by 0.55 ng/mL (43.8%; p < 0.001), which is of paramount clinical importance.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective cohort study conducted in a tertiary university hospital comprised patients (n = 52) who self-administered daily triptorelin (0.1 mg/0.1 mL) subcutaneously for 14 days from menstrual cycle day 21 ± 3, between July 2015 and March 2016.
Summary · context
Enrolled women were 18-43 years old, considered normal ovarian responders, with a planned GnRH agonist controlled ovarian stimulation protocol.
Show in the study text Report a problemFND-3086336703
04HumanObservational studyOther
In normal ovarian responders, triptorelin treatment duration remained significantly associated with AMH after adjustment for confounders.
In plain wordsIn normal ovarian responders, triptorelin treatment duration was linked to AMH changes after adjustment for other factors.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedAdjusted association with AMH concentration
Study
n = 52
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
A linear, mixed-effect model demonstrated that GnRH agonist treatment for 7 and 14 days had a highly significant effect on serum AMH concentration after adjustment for confounding factors (age, body mass index, baseline antral follicle count, and visit).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective cohort study conducted in a tertiary university hospital comprised patients (n = 52) who self-administered daily triptorelin (0.1 mg/0.1 mL) subcutaneously for 14 days from menstrual cycle day 21 ± 3, between July 2015 and March 2016.
Summary · context
Enrolled women were 18-43 years old, considered normal ovarian responders, with a planned GnRH agonist controlled ovarian stimulation protocol.
Show in the study text Report a problemFND-3086336704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.